| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -618,466 | -578,480 | -537,919 | -1,395,817 |
| Depreciation expense | 22,256 | 23,912 | 23,148 | 38,403 |
| Stock-based compensation | 23,527 | 23,527 | 19,915 | 42,544 |
| Non-cash interest expense | 174,635 | NaN | NaN | NaN |
| Provision for credit losses | 0 | 50,000 | 28,876 | 12,525 |
| Provision for inventory obsolescence | 0 | 10,252 | 0 | 9,119 |
| Vendor expense settled in shares of common stock | 18,000 | 18,000 | 18,000 | 15,000 |
| Gain on settlement of accounts payable | NaN | 0 | NaN | NaN |
| Amortization of operating lease right of use assets | 18,942 | 18,498 | 18,073 | 34,905 |
| Accounts receivable, net | 312,002 | -40,585 | 360,688 | 84,760 |
| Inventory, net | 34,776 | 22,386 | 35,811 | 24,493 |
| Prepaid expenses and other current assets | 78,699 | -38,468 | 43,307 | -108,515 |
| Accounts payable | -50,848 | -55,576 | 178,775 | 93,694 |
| Accrued expenses | 99,497 | 102,900 | 76,338 | 22,154 |
| Deferred revenue | -27,941 | -75,000 | -75,000 | 1,425,000 |
| Operating lease liabilities | -18,397 | -17,346 | -16,916 | -32,598 |
| Net cash used in operating activities | -784,272 | -422,646 | -706,516 | 264,191 |
| Purchases of property and equipment | 847 | 43,205 | 0 | 231,551 |
| Net cash used in investing activities | -847 | -43,205 | 0 | -231,551 |
| Net proceeds from issuance of common stock | NaN | 0 | 791,418 | 0 |
| Net proceeds from option exercises | NaN | 0 | 113,541 | NaN |
| Net proceeds from note payable issuance related party-Nonrelated Party | NaN | 300,000 | NaN | NaN |
| Net proceeds from note payable issuance related party-Related Party | NaN | 200,000 | NaN | NaN |
| Net proceeds from warrant exercise | NaN | 0 | 0 | 0 |
| Net proceeds from notes payable issuance | 500,000 | NaN | NaN | NaN |
| Net cash provided by financing activities | 500,000 | 500,000 | 904,959 | 0 |
| Net increase (decrease) in cash | -285,119 | 34,149 | 198,443 | 32,640 |
| Cash, beginning of period | 548,946 | 514,797 | 283,714 | NaN |
| Cash, end of period | 263,827 | 548,946 | 514,797 | NaN |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)